Drugs / NS-863
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy2 trials | ||||||
| Phase 2 | NCT07441278 Comparator | Jul 2026 → Sep 2028 expected | pulmonary hypertension owing to lung disease and/or hypoxia | NS Pharma, Inc. | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07441200 Comparator | Jul 2026 → Aug 2028 expected | pulmonary arterial hypertension | NS Pharma, Inc. | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NS-863 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07441278 ↗ |
| Route | Oral | “NS-863 is an orally administered drug” NCT07441200 ↗ |